Cardinal Health to Collaborate with Wyeth on Cell Line Development
Complete the form below to unlock access to ALL audio articles.
Cardinal Health has announced it has entered a feasibility agreement with Wyeth, acting through its Wyeth Pharmaceuticals division, to develop cell lines using Cardinal Health’s Gene Product Expression (GPEx®) cell line engineering technology.
Cardinal Health will use its patented GPEx® technology to engineer cell lines that express two undisclosed biopharmaceutical molecules in experiments that will determine if the GPEx® approach is a feasible augmentation to Wyeth’s current production methods.
"Wyeth has taken a leadership position among major pharmaceutical companies to seriously move into large molecule therapeutics and has a great track record with biopharmaceutical R&D, manufacturing and commercialization," said Paul Weiss, PhD, president of Cardinal Health’s biopharmaceutical development services center.
"We feel confident that the speed and high expression capabilities of our GPEx® technology will be attractive to Wyeth as they evaluate additional platforms to rapidly and cost-effectively produce biopharmaceuticals."
